Goodwin advised Tessera Therapeutics on the deal.Tessera Therapeutics announced its Series C financing, which totaled over $300 million. Tessera is a biotechnology company pioneering a new…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
